The FDA is mired in uncertainty with some staffers losing their jobs over the weekend and more potentially to come, vaccines ...
UBS lowered the firm’s price target on Moderna (MRNA) to $78 from $96 and keeps a Buy rating on the shares. UBS believes Moderna’s oncology ...
EPS estimates but beats revenue expectations. Barclays downgrades stock, citing COVID demand decline and RSV uptake ...
Moderna said on Friday that the U.S. FDA paused a late-stage trial of its experimental norovirus vaccine after a case of a ...
Moderna Inc. recorded another quarterly loss as vaccine sales wane and the company had an unexpected charge for a canceled ...
Barclays downgraded shares of Moderna (NASDAQ:MRNA – Free Report) from an overweight rating to an equal weight rating in a report published on Tuesday, Ratings reports. The firm currently has $45.00 ...
BofA analyst Tim Anderson lowered the firm’s price target on Moderna (MRNA) to $32 from $34 and keeps an Underperform rating on the shares.
Moderna is revamping its digital team, eliminating 10% of roles under two digital departments, affecting about 50 employees, ...
Moderna, Inc. (NASDAQ:MRNA – Get Free Report) was the recipient of unusually large options trading on Tuesday. Stock investors bought 179,268 call options on the company. This represents an increase ...
Biotech firm Moderna reported a bigger-than-expected quarterly loss on Friday, hit by a charge related to its efforts to ...
A trial of Moderna’s norovirus vaccine in the U.S. has been put on hold by the FDA over a reported case of neurological ...
It marks another quarter of growing pains for the company, which is racing to launch new products and recover from the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results